报告人基本信息：

Peter Lobie obtained a B.Med.Sci. (Distinction) and MBBS (Medicine First Class Honours) in 1992 from the University of Queensland in Australia. He was awarded the highest accolade from the University in the form of a University Medal. His postdoctoral work was undertaken at the Karolinska Institute in Sweden where he also obtained his doctoral degree (PhD). He has consecutively held faculty positions in Sweden, Singapore and New Zealand. He was also New Zealand’s first chair of Breast Cancer funded by the Breast Cancer Research Trust. He was Professor and Senior Principal Investigator at the Cancer Science Institute of Singapore before being appointed co-Director of the Centre for Precision Medicine and Healthcare at the Tsinghua-Berkeley Shenzhen Institute.

Peter Lobie is author of over 190 publications and is an internationalSinotar Therapeutics Ltd, two new entities focused on development of therapeutics to novel cancer target molecules. He is/was an editorial board member of Endocrinology and Molecular Endocrinology, among a number of other international journals and served on the Annual Meeting Steering Committee of The Endocrine Society (USA). He has served as a reviewer for more than 70 academic journals and more than 15 local and international granting agencies.